Global policy and advocacy

The World Federation of Hemophilia (WFH) plays a leadership role in global advocacy by convening the global bleeding disorders community to promote equitable access to care and to current and emerging treatments. We leverage global and regional advocacy work to enhance the impact of national advocacy initiatives related to policy, care delivery and procurement.

WORLD HEALTH ASSEMBLY RESOLUTION

On May 22nd, 2026, the 79th World Health Assembly (WHA) unanimously adopted a resolution on Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders, following the approval of the World Health Organization (WHO) Executive Board during its 158th session on February 3rd, 2026.

What is a World Health Assembly (WHA) Resolution?

A World Health Assembly Resolution is an official WHO policy document adopted by the WHO Member states to set global health priorities and policies, guide national health strategies and request specific actions from the WHO Secretariat. Although not legally binding under international law, these resolutions represent a significant international policy instrument and a political commitment, as they are adopted by the consensus of all the WHO Member States.

About the WHA Resolution on Hemophilia and Other Bleeding Disorders

Armenia delegation presenting to the Executive Board of the WHO, February 2nd 2026

The WFH applauds the WHO Member States—Armenia (the proponent country) for their leadership of this important initiative, and the co-sponsors Bosnia & Herzegovina, China, Egypt, Georgia, Iraq, Latvia, Malta, Morocco, Nepal, Paraguay, the Russian Federation, Slovenia, Spain, Sri Lanka and Togo. The WFH—as a non-state actor in official relations with the WHO—has been advocating for, and strongly supported the adoption of this WHA79 resolution Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders.


The WHA resolution at a glance:

Section 1

Section 1 is the preamble that highlights key disparities that people with bleeding disorders face in terms of underdiagnosis and inequitable access to treatment and care, regardless of type of bleeding disorder, gender or where they live. It also outlines already-existing key United Nations (UN) and WHO international policy documents that the proposed resolution is in alignment with.

Section 2

Section 2 includes the main recommendations that the resolution urges all Member States to implement at the country level, focusing on the following main areas:

  • Include hemophilia and other bleeding disorders in relevant national health policies
  • Increase capacity in diagnosis and management of bleeding disorders and comprehensive care services
  • Enhance equitable access to safe, effective and affordable medicines, prophylaxis and home treatment, including existing and novel emerging therapies
  • Strengthen national data collection systems
  • Implement programs that promote mental health and psychosocial support for PWBDs and their families
  • Promote public awareness and education on bleeding disorders to reduce misconceptions and stigma, including for women and girls with bleeding disorders (WGBD)
  • Empower people with bleeding disorders (PWBDs) and engage organizations representing them by establishing consultative mechanisms
  • Recognize and celebrate World Hemophilia Day on April 17th in collaboration with civil society and other stakeholders
Section 3

Section 3 outlines concrete actions for the WHO to implement, including the following:

  • Assess and map existing WHO guidance and recommendations on hemophilia and other bleeding disorders
  • Develop WHO recommendations for Member States on strengthening hemophilia and other bleeding disorders responses within relevant health policies, treatment financing mechanisms and multidisciplinary care
  • Recognize World Hemophilia Day on April 17 as a global health day
  • Report biennially to the WHA on the implementation of the resolution as part of the global agenda for non-communicable diseases

What impact can the resolution have on our community?

By adopting the WHA resolution on Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders, the WHO and its Member States (national governments) will recognize bleeding disorders as a global health priority and take critical step towards developing a coordinated global framework and concrete actions to address the health inequities affecting our community.

Formal Steps for adoption of a WHA Resolution

1
Lead proponent Member State/s propose a discussion on the resolution to WHO Secretariat
September 2025
2
Lead Member State submits Consent Note and Zero Draft Resolution to WHO Secretariat
October 2025
3
Intergovernmental consultations on the zero draft – to reach consensus and confirm co-sponsor Member States
Dec '25 – Jan '26
4
Final draft of the resolution submitted for 158th Session of the WHO Executive Board
January 2026
5
Discussion and decision to approved draft resolution by WHO Executive Board
February 2 – 3 2026
6
Final decision on resolution adoption at 79th World Health Assembly
May 18 – 23 2026

WFH Global Call for Health Equity for Bleeding Disorders

The World Federation of Hemophilia (WFH) has launched a Global Call for Health Equity for Bleeding Disorders in support of the adoption of the World Health Assembly (WHA) resolution on Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders.

The WFH invites all our national member organizations (NMOs) and collaborating patient, medical and scientific associations to join the WFH Global Call for Health Equity for Bleeding Disorders to support of the effective implementation of the now adopted landmark resolution. There are two ways organizations can get involved:

  1. Approach your Ministry of Health or another decision maker and request that they uphold the commitments made by all Member States through the implementation of this resolution which was adopted unanimously at the 79th World Health Assembly on May 22nd, 2026
  2. Email the WFH ([email protected]) and request to join our Global Call for Health Equity for Bleeding Disorders
Representatives from the WFH and Armenia at the WHA Side-Event: Advancing Health Equity for Bleeding Disorders, May 17th 2026
One of the panel discussions at the WHA Side-Event: Advancing Health Equity for Bleeding Disorders, May 17th 2026

We are grateful for the support of the 105+ organizations that have already joined our Global Call.

R1
1
R2
2
3
R3
4
5
6
R4
7
8
9
R5
10
11
12
13
14
R6
15
16
17
18
19
R7
20
21
22
23
24
25
26
R8
27
28
29
30
31
32
33
R9
34
35
36
37
38
39
40
41
42
R10
43
44
45
46
47
48
49
50
51
52
53
R11
54
55
56
57
58
59
60
61
62
63
64
R12
65
66
67
68
69
70
71
72
73
74
75
R13
76
77
78
79
80
81
82
83
84
R14
85
86
87
88
89
90
91
R15
92
93
94
95
96
R16
97
98
99

Related resources:

WFH presenting to the World Health Assembly, May 21, 2026

The WFH participated in the 79th World Health Assembly, making a statement in support of the adoption of the resolution on Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders.


Decision on the Resolution, World Health Assembly, May 21, 2026

The 79th World Health Assembly unanimously adopted the resolution on Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders.


79th World Health Assembly Side-Event: Advancing Health Equity for Bleeding Disorders, May 17th 2026

This World Health Assembly Side-Event offered inspiring opening addresses and two expert panel discussions, underlying the importance of the adoption of the WHA resolution on Global Action to Advance Health Equity for People with Bleeding Disorders Worldwide.


Armenia delegation presenting to the Executive Board of the WHO, February 2nd 2026

During the 158th session of the WHO Executive Board, Armenia introduces the resolution on Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders.


WFH presenting to the Executive Board of the WHO, February 2nd 2026

The WFH participated in the 158th session of the WHO Executive Board, urging the WHO and its Member States to adopt the resolution on Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders.


Webinar: WHA Resolution on Health Equity for Hemophilia and Other Bleeding Disorders

On January 29th, 2026 the WFH hosted an informational webinar on the progress made for the adoption of a World Health Assembly (WHA) resolution on hemophilia and other bleeding disorders.

WHO ESSENTIAL MEDICINES LISTS

Collaboration with international inter-governmental agencies is instrumental to achieving the mission of the WFH. The federation has been a non-state actor in official relations with the World Health Organization (WHO) since 1969, which has allowed it to effectively represent the bleeding disorders community’s voice with international healthcare stakeholders and decision-makers.

The WHO Model Lists of Essential Medicines includes medicines that meet the priority healthcare needs of a population, selected based on their efficacy, safety and cost-effectiveness. The model lists include the Essential Medicines List (EML) and the Essential Medicines List for Children (EMLc) that are updated by the WHO every two years and serve as a WHO guiding framework for national governments on the selection and financing of essential medicines for a range of conditions, including bleeding disorders.

A concerted effort by the WFH and its partners has led to the WHO updating its 24th Essential Medicines List (EML) and the 10th Essential Medicines List for Children (EMLc) to better align the EMLs to the international clinical guidelines for the management of hemophilia and von Willebrand Disease (VWD). These critical revisions will have a positive impact on lives of people with bleeding disorders (PWBDs) everywhere.

The specific changes made to 24th EML and 10th EMLc for treatment of hemophilia and VWD include:

New medicines added to the EML and EMLC
  • Bi-specific monoclonal antibody, emicizumab: included on the core list
  • Recombinant FVIII and FIX CFCs: included on the core list
Revisions made to existing medicines listed on EML and EMLc
  • Plasma-derived FVIII and FIX CFCs: transferred from the complementary to the core list
  • Desmopressin: transferred from the complementary to the core list
Medicines or formulations deleted on EML and EMLc
  • Pathogen-reduced (PR) and non-PR cryoprecipitate: removed as indications for hemophilia and VWD
  • Factor IX Complex (prothrombin complex concentrate (PCC): deleted as a therapeutic alternative to FIX CFCs

Learn more and see related resources below:

Webinar: WHO Essential Medicines List 2025 Update

Recent milestone revisions to the World Health Organization (WHO) Essential Medicines List (EML) are covered in this webinar: “WHO Essential Medicines List 2025 Update: Impact on Bleeding Disorders Community” which shows how these revisions can be leveraged to have a positive impact on lives of people with bleeding disorders everywhere.


WFH expert panel video on the WHO EML and EMLc update

This expert panel discussion covers 2025 updates to the WHo EML and EMLc and their impact on the bleeding disorders community.

PACT

PACT Logo

The new WFH Path to Access to Care and Treatment (PACT) Program is a 5-year initiative, ending in 2025 designed to improve outreach and diagnosis and increase access to sustainable care for people with inherited bleeding disorders. This will be achieved through training, education, partnerships, in-country initiatives, and evidence-based advocacy. To see the 2-year update on the WFH PACT program, click here.

The need

People with bleeding disorders’ communities face many challenges getting access to proper care in many countries around the world. The gap between observed versus expected people with hemophilia is even greater than it was estimated in the past—with only one third of the expected number of people with hemophilia having been identified globally so far. PACT aims to support the global bleeding disorders community by addressing these needs.

Pact goals

The PACT Program aims to:

  • Identify 20,000 new people with inherited bleeding disorders
  • Improve access to care through the training and education of patient leaders and healthcare providers on outreach, diagnosis, the management of bleeding disorders, and evidence-based advocacy
  • Increase government support to establish or expand existing national bleeding disorders care programs

Program components

The Program will be implemented through three key components.

The PACT Advocacy Academy provides NMO leaders and patient advocates with the necessary knowledge and skills to carry out successful evidence-based advocacy campaigns, including basic concepts and principles of care, access to therapies and procurement, an introduction to health economics, and the design and implementation of advocacy programs.

Yearly virtual training sessions for healthcare professionals focus on outreach, diagnosis, and the management of bleeding disorders. Ongoing training outcomes evaluation will be carried out to provide an assessment of additional needs and to gauge the capacity for progress.

Tailored 4 to 5-year national access plans include personalized training, and on-the-ground support for outreach and advocacy campaigns to increase support from national governments. Collaboration between main stakeholders—the NMO, healthcare professionals and national governments—will be fostered to maximize the success of these programs.

Mentorship from subject-matter experts for NMOs in target countries support the implementation of national access plans. The duration of these mentorships can be from 6-months to 4-years, depending on local needs.

Global and regional training and meetings (starting in 2022) will serve as a forum for sharing best practices and experiences on evidence-based advocacy between community leaders. These collaborative forums will bring together NMO leaders, healthcare professionals and government representatives to promote dialogue and increase engagement among stakeholders.

The WFH is looking for volunteer subject matter experts to serve as WFH PACT Program mentors for NMOs in target countries and to support the implementation of their national access plans. 

OBJECTIVE

The main objective of mentorship is to provide guidance and expertise to WFH NMOs in one or more of the thematic or organizational capacity areas listed below to maximize the impact of their PACT national access plans.

DURATION

The duration of mentorship will range from six months to four years and will be defined on a case-by-case basis, depending on local needs and the mentor’s availability.

AREAS OF EXPERTISE

The WFH is seeking mentors with extensive experience and expertise in one or more of the following areas: 

National bleeding disorders programs and care delivery

  • Developing a national bleeding disorders (or hemophilia) program
  • Establishing national hemophilia or bleeding disorders councils or committees
  • Developing national treatment guidelines
  • Establishing hemophilia treatment centres

Advocacy and government support

  • Planning and implementing advocacy campaigns
  • Collecting and using data for advocacy
  • Understanding health economics and health technology assessments
  • Increasing access to safe therapies and procurement models
  • Managing relations with stakeholders

NMO organizational capacities and leadership

  • Supporting governance and leadership development
  • Enhancing NMO organizational development, including regional representation or chapters
  • Developing strategic plans
  • Writing a project proposal and managing project cycle
  • Developing communications plans
  • Engaging and retaining volunteers
  • Implementing fundraising and resource mobilization campaigns

NMO outreach and educational programs and services

  • Designing and implementing outreach programs to identify new people with bleeding disorders
  • Using digital tools in outreach and/or educational programs
  • Designing and implementing thematic projects related to any of the following:
    • Awareness and education on VWD
    • Youth leadership and engagement
    • Awareness and education on issues related to women and girls with inherited bleeding disorders
  • Designing and implementing other patient or healthcare education and capacity-building programs
  • Developing patient registries and other data collection programs

how mentorship works

All individuals who apply to join the PACT Program as a mentor will receive a letter of acknowledgement and will be added to a database of prospective mentors. A matching process will follow, taking into consideration the mentor’s expertise and the needs of NMOs currently implementing national projects as part of the PACT Program. Once a suitable match is established, the mentor will be contacted to confirm their selection.

Next, an introductory meeting between the mentor and the NMO will be facilitated by WFH staff to discuss the objectives and scope of the mentorship and establish both parties’ willingness to work together. Once a mentorship starts, the WFH will ask both the mentor and the NMO to provide periodic progress reports.

Here are some examples of the type of support a mentor could provide to an NMO:

  • Provide guidance and advice on specific areas as defined in the agreed upon scope of mentorship
  • Review and provide feedback on various documents, policies, and guidelines (either national or internal for the NMO)
  • Present at a meeting or an event as a subject-matter expert

How to apply to become a WFH PACT Program mentor

Interested individuals with demonstrated experience and expertise in one of the areas listed above are invited to send their CV and the completed Mentor Expression of Interest Form to [email protected].

Introducing our 2025 Impact Report!

Discover the transformative outcomes of our initiatives, showcasing the positive change we have contributed to in the global bleeding disorders community.

Participating countries

The online training and education and the global and regional meeting components of PACT are available to all countries, while 20 countries have been selected to work on the development and implementation of national access plans. Countries are selected based on the following criteria:

  • Demographic and economic indicators
  • Strength and commitment of local leadership
  • Level of bleeding disorders care in their healthcare system
  • Overall potential for success

The following countries are enrolled in PACT: Argentina, Bangladesh, Bolivia, Brazil, China, Costa Rica, Egypt, India, Indonesia, Kenya, Malaysia, Mexico, Nepal, Nigeria, Pakistan, Palestine, Senegal, Uzbekistan, Vietnam, and Zambia.

The PACT program is supported by funding from:

VISIONARY PARTNER
LEADERSHIP PARTNERS
COLLABORATING PARTNER

PACT ADVOCACY ACADEMY

The pages of an open notebook connect with the back of a laptop

The newly revised PACT Advocacy Academy provides NMO leaders and advocates with the necessary knowledge and skills to carry out successful evidence-based advocacy campaigns with increased focus on treatment access. The three-month course includes the following topics:

  • Existing and novel treatments for bleeding disorders
  • Data-driven determinants of health
  • International policy instruments (WHA Resolution, WHO Essential Medicines List, etc)
  • Key elements of developing a policy brief
  • Procurement mechanisms
  • Introduction to health economics

For more information please email [email protected].

The course is currently offered in English.


“One of the main learnings for me from the PACT Advocacy Academy was using systemic thinking to manage advocacy projects. I have applied stakeholder analysis in my advocacy work and conducted workshops about stakeholder mapping … to share my learnings with the Thai hemophilia youth group and with other rare disease patient groups.” – Ekawat Suwantaroj, WFH Board Member and Thai Hemophilia Foundation

“I would like to thank WFH for providing me with such a beautiful opportunity of studying with people of different regions.” – Participant, 2022


New York University Logo

This course is created in collaboration between the World Federation of Hemophilia (WFH), the New York University Robert F. Wagner Graduate School of Public Service (NYU Wagner) and an expert working group.

Each topic takes place over three to four weeks and includes one self-directed online learning module and two live interactive webinars. An online platform allows participants to track their progress and refer to previous modules.

Over the duration of the course, participants are required to develop their own real-life policy brief for their NMO. For participants from PACT countries, this should be aligned with the PACT national access plan.

Learn more about the Advocacy Initiatives from WFH PACT Advocacy Academy:

If you have any questions about PACT Advocacy Academy program, please contact the WFH at [email protected].

EVIDENCE-BASED ADVOCACY

Data collected through WFH data collection programs are used to highlight discrepancies in care around the world, and create graphs, charts, infographics, and tools that can be used by NMOs and HCPs to help strengthen advocacy messaging.

The WFH has developed a user-friendly data visualization system, which includes real-time, customizable queries. This system allows the user to explore and compare recent and historical data to suit all reporting, research, and advocacy needs.

View and download graphs of AGS data developed using our new data collection system.

WFH AGS mini reports are advocacy tools that provide more in-depth perspective and context to AGS data.

Peer-reviewed publications on global data and patient registries relevant to hemophilia and other bleeding disorders are also available.

Stonebraker JS, Bolton-Maggs PHB, Brooker M, Evatt B, Iorio A, Makris M, O’Mahony B, Skinner MW, Coffin D, Pierce GF, Tootoonchian E, The World Federation of Hemophilia Annual Global Survey 1999‐2018. Haemophilia. 2020 Jul;26(4):591-600. doi: 10.1111/hae.14012. Epub 2020 Jun 4.

Iorio A, Stonebraker JS, Chambost H, Makris M, Coffin D, Herr C, Germini F; Data and Demographics Committee of the World Federation of Hemophilia, Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. Ann Intern Med. 2019 Oct 15;171(8):540-546. doi: 10.7326/M19-1208. Epub 2019 Sep 10.

Coffin D, Herr C, O’Hara J, Diop S, Hollingsworth R, Srivastava A, Lillicrap D, van den Berg HM, Iorio A, Pierce GF. World bleeding disorders registry: The pilot study. Haemophilia. 2018 Feb;e113-e116.

Iorio, A., Stonebraker, J. S., Brooker, M., Soucie, J. M. on behalf of the Data and Demographics Committee of the World Federation of Hemophilia (2017), Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data. Haemophilia. 2017 Jan;23(1):e1-e7. doi: 10.1111/hae.13127. Epub 2016 Dec 8.

GENE THERAPY ROUND TABLE SERIES

The WFH Gene Therapy Round Table (GTRT) series was held from 2018 to 2022. It brought national member organizations (NMOs), patient advocates, healthcare professionals (HCPs), regulators and industry representatives together to share a dialogue on current global developments and the expected challenges related to gene therapy for hemophilia.

Interested in more events about Gene Therapy? The WFH will be hosting a New Technology and Gene Therapy Workshop in November 2024. Contact [email protected] to learn more.

Objectives

The objective of this series was to foster a better understanding of the challenges related to the development of gene therapy for people with hemophilia (PWH) around the world. Key challenges and discussions centred around global access to gene therapy, regulatory and financial challenges, the unknowns of gene therapy and long-term follow-up of safety and efficacy. Multi-stakeholder and global perspectives were also considered. The reports from the WFH GTRT have been published.

Gene Therapy Round Table Program Committee

Chair
Glenn Pierce, U.S.A.

Members
A revolving committee of eight health care professionals (HCPs), and people with a bleeding disorder and/or caregiver make up the program committee.

Previous programs are available here:

WFH GTRT PROGRAMS

Did you know?

The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support to NMOs, HTCs, and HCPs in emerging countries.

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.